DartLab offers a range of services to facilitate Phase I and II clinical trials, including panel development, cell staining, cell sorting, flow cytometry, and data analysis. To arrange services for a clinical trial, please contact Dr. Smith to consult on research needs and experimental design.
Previous Clinical Trials
| Title | Phase | PI | Category
*by DartLab |
|
| Treatment of multiple sclerosis with anti-CD154: a phase II double-blind partial cross-over clinical trial (IDEC/ITN). | Mechanistic | Kasper | monitoring* | |
| A trial of a CD40 activated dendritic cell vaccine in patients with resected colorectal cancer (NCI). | Phase II | Barth | vaccine/monitoring* | |
| The effect of CNTO 1275 on the immune responses of peripheral blood cells from subjects with relapsing forms of multiple sclerosis (Centocor). | Mechanistic | Kasper | monitoring* | |
| Dose-escalation study of EMD 273066 administered with low-dose cyclophosphamide to subjects with epithelial cell adhesion molecule (EpCAM) positive advanced cancers. | Phase I | Ernstoff | cellular | |
| Dose dependent induction of T regulatory cells by glatiramer acetate: a parallel mechanistic study to GA9016 (TEVA Pharmaceuticals) | Mechanistic | Kasper | monitoring* | |
| Longitudinal study of mild cognitive Iimpairment and early Alzheimer’s disease. | Monitor | Saykin | cytokine* | |
| Autologous PBSC and immunotherapy for myeloma. | Phase III | Meehan | cellular/cytokine | |
| Immune mobilization of autologous PBSC with IL-2 and GM-CSF | Phase III | Meehan | cytokine | |
| Immunologic evaluation of peripheral blood. | Monitor | Ernstoff | monitoring | |
| Autologous tumor/DC vaccine + IL-2 & IFNα in renal cell cancer. | Phase II | Ernstoff | vaccine/cytokine | |
| Pre-clinical studies for development of a DC in GBM | Pilot | Fadul | vaccine | |
| IL-2 in lymphodepleted primed melanoma patients. | Phase II | Ernstoff | cytokine | |
| Adjuvant intra-nodal autologous DC in GBM. | Phase II | Fadul | vaccine | |
| Cryoablation as immunomodulator in breast cancer (Sanarus). | Pilot | Barth | vaccine/monitoring* | |
| VEGF blockade autologous DC, IL-2, and IFNa-2b in renal cell cancer. | Phase II | Ernstoff | vaccine/cytokine | |
| Cellular immunoRx, after autologous PBST for myeloma. | Phase II | Meehan | cellular | |
| Modulation of immune system by VEGF in GBM. | Pilot | Fadul | antibody | |
| Melanoma and renal tumor tissue bank extension. | Monitor | Ernstoff | monitoring | |
| Immune endpoints in blood & BM myeloma and healthy subjects. | Monitor | Meehan | monitoring | |
| Immunological effects of GM-CSF/vaccine in renal cell cancer and melanoma. | Pilot | Ernstoff | vaccine/cytokine | |
| Leukapheresis for immunological endpoints. | Monitor | Ernstoff | monitoring | |
| GM-CSF in patients with prostate cancer. | Pilot | Ernstoff | cytokine | |
| Bevacizumab + IL-2 in renal cell cancer. | Phase II | Ernstoff | cytokine/antibody | |
| Melacine plus IFNa-2b vs. IFNa-2b in melanoma. | Phase III | Ernstoff | vaccine/cytokine | |
| Induction of T regulatory cells in relapsing-remitting multiple sclerosis following treatment with anti-CD52 (Campath 1-H; Genzyme) | Mechanistic | Kasper | cellular/ cytokine/monitoring* | |
| Induction of T regulatory cells and the effect on B cells by IFNb-1b (Bayer) | Mechanistic | Kasper | monitoring* | |
| The relationship between thymic activity, regulatory T-cells and functional immune status in organ transplantation with alemtuzumab (Campath-1H) pretreatment and tacrolimus monotherapy. | Pilot | Zuckerman | cellular/monitoring* | |
| The effect of psychosocial and behaviorally-based interventions on biological outcomes of patients with an advanced cancer diagnosis (NIH). | Pilot | Bakitas | cellular/ cytokine/monitoring* | |
| Evaluation of the effect of age and prior immunity on the response to live or inactivated seasonal influenza vaccines in children (NIH). | Pilot | Wright | cellular/cytokine/monitoring* | |
| An open-label, dose-escalation, phase I study of the safety, tolerability and immunogenicity of the prime-boost regimen of the investigational 2012/13 seasonal influenza DNA vaccine followed by the 2012/2013 seasonal influenza trivalent inactivated vaccine (TIV) compared to TIV prime-TIV boost in children and adolescents ages 6-17 Years (NIH). | Phase I | Wright | cellular/cytokine/monitoring* | |
| Immune monitoring of the effects of an RXR nuclear receptor agonist on peripheral blood mononuclear cells from patients with Parkinson’s disease (Io Therapeutics, Inc.). | Phase I | Channon | cellular/cytokine/monitoring* | |
| Pilot studies to determine the effects of an RXR nuclear receptor agonist on peripheral blood mononuclear cells from healthy individuals (Io Therapeutics, Inc.). | Pilot | Channon | cellular/cytokine | |
| Pilot study to evaluate the efficacy and safety of plasma exchange with human albumin in patients with amyotrophic lateral sclerosis (Grifols Biologicals Inc.). | Phase I | Channon | cellular/cytokine/monitoring* | |
| A Phase I Study of De-immunized DI-Leu16-IL2 Immunocytokine administered subcutaneously in Patients with B-cell Non-Hodgkin Lymphoma (Alopexx Pharmaceuticals LLC). | Phase I | Channon | cellular/cytokine/monitoring* | |